Evidence map›Paper›PMID 34696438›Full record

ArticleViruses2021

Role of Serum Vitamin D, Interleukin 13, and microRNA-135a in Hepatocellular Carcinoma and Treatment Failure in Egyptian HCV-Infected Patients Receiving Direct Antiviral Agents.

Mohamed E Ali, Hamada M Halby, Mamdouh Yones Ali, Elham Ahmed Hassan, Mohamed A El-Mokhtar, Ibrahim M Sayed, Marwa M Thabet, Magdy Fouad, Ahmed M El-Ashmawy, Zainab Gaber Mahran

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Viruses, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Mohamed E AliDepartment of Microbiology and Immunology, Faculty of Pharmacy, Al-Azhar University, Assiut 71524, Egypt.
Hamada M HalbyDepartment of Microbiology and Immunology, Faculty of Pharmacy, Al-Azhar University, Assiut 71524, Egypt.
Mamdouh Yones AliDepartment of Microbiology and Immunology, Faculty of Pharmacy, Al-Azhar University, Assiut 71524, Egypt.
Elham Ahmed HassanDepartment of Gastroenterology and Tropical Medicine, Faculty of Medicine, Assiut University, Assiut 71515, Egypt.
Mohamed A El-MokhtarDepartment of Medical Microbiology and Immunology, Faculty of Medicine, Assiut University, Assiut 71515, Egypt.ORCID 0000-0003-1943-8419
Ibrahim M SayedDepartment of Medical Microbiology and Immunology, Faculty of Medicine, Assiut University, Assiut 71515, Egypt.ORCID 0000-0001-8207-6401
Marwa M ThabetDepartment of Clinical Pathology, Faculty of Medicine, Assiut University, Assiut 71515, Egypt.
Magdy FouadHepato-Gastroenterology Unit, Tropical Medicine Department, Faculty of Medicine, El-Minia University, Minya 61519, Egypt.
Ahmed M El-AshmawyGastroenterology and Hepatology Unit, Department of Internal Medicine, Faculty of Medicine, Assiut University, Assiut 71515, Egypt.
Zainab Gaber MahranDepartment of Gastroenterology and Tropical Medicine, Faculty of Medicine, Assiut University, Assiut 71515, Egypt.
Assiut University · EGAl-Azhar University · EGMinia University · EG

Funding

Faculty of Medicine Assiut University, Egypt 006-27-07-2020
6 · The paper itself

Abstract

Direct-acting antivirals (DAAs) are used for hepatitis C virus (HCV) treatment. However, treatment failure and hepatocellular carcinoma (HCC) development following treatment was reported. In this study, we assessed the role of serum vitamin D, interleukin 13 (IL-13), and microRNA-135a in the prediction of treatment failure with DAA and HCC development among Egyptian HCV-infected patients. A total of 950 patients with HCV-related chronic liver disease underwent DAA treatment. Before DAAs, serum vitamin D and IL-13 were determined by ELISA, and gene expression of miRNA-135a was assessed in serum by real-time PCR. The predictive abilities of these markers were determined using the receiver operating characteristic (ROC) curve. Sustained virological response (SVR) was achieved in 92.6% of HCV-infected patients (responders). High viral load, IL-13, miRNA-135a, and low vitamin D levels were associated with treatment failure and HCC development. HCC development was recorded in non-responders, but not in the responders (35.7% vs. 0%

Indexed as

AdultAgedAntiviral AgentsCarcinoma, HepatocellularEgyptFemaleHepacivirusHepatitis CHumansInterleukin-13Liver NeoplasmsMaleMicroRNAsMiddle AgedTreatment FailureViral LoadAntiviral AgentsIL13 protein, humanInterleukin-13MicroRNAsMIRN135 microRNA, humanVitamin DHCCHCVIL-13miRNA-135aprognostic markervit D

Identifiers

PMID34696438
PMCPMC8539757
OpenAlexW3204218909

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.